

ASX Release

SUDA LTD ANNOUNCES NEW MEDIA ARTICLE

PERTH, AUSTRALIA – 23 August 2017: SUDA LTD (ASX: SUD), a leader in oro-mucosal drug delivery, today announces that Tim Boreham, an independent journalist, published an article on SUDA in Biotech Daily, an Australian biotech stock report, on 18 August 2017. The article is available on the Company's website via the following link:

<http://www.sudaltd.com.au/index.php/media-news>

Tim Boreham is an experienced business writer, with over three decades at major business publications covering life sciences and other sectors. Tim was best known as writer of The Australian's Criterion investment column, which analysed listed companies — both large and small — in a way that was accessible to retail investors. A quirk of the column was that it offered 'buy' and 'sell' recommendations in a journalist context.

Separately, Bioshares, another leading Australian biotech stock report, published an article on SUDA on 18 August 2017 in edition number 709 of the Bioshares publication. Bioshares rated SUDA as *Speculative Buy Class B*.



Further information:

STEPHEN CARTER

CHIEF EXECUTIVE OFFICER / MANAGING DIRECTOR

SUDA LTD

Tel: +61 8 6142 5555

sjcarter@sudaltd.com.au

NOTES TO EDITORS:

About SUDA LTD

SUDA LTD (ASX: SUD) is a drug delivery company focused on oro-mucosal administration, headquartered in Perth, Western Australia. The Company is developing low-risk oral sprays using its OroMist® technology to reformulate existing pharmaceuticals. The many potential benefits of administering drugs through the oral mucosa (i.e.: cheeks, tongue, gums and palate) include ease of use, lower dosage, reduced side effects and faster response time. SUDA's product pipeline includes ZolpiMist™, a first-in-class oral spray of zolpidem for insomnia. ZolpiMist is marketed in the USA and SUDA has rights to the product outside of the US and Canada. SUDA's most advanced development-stage product, ArTiMist®, is a novel sublingual malaria treatment for children. In a Phase III trial, ArTiMist was shown to be superior to intravenous quinine. Other products in development include oral sprays for the treatment of migraine headache, chemotherapy-induced nausea and vomiting, erectile dysfunction and pre-procedural anxiety. For more information, visit www.sudaltd.com.au